2017
DOI: 10.1093/schbul/sbx065
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 14 publications
(10 citation statements)
references
References 72 publications
(77 reference statements)
0
9
0
Order By: Relevance
“…Nevertheless, the mouse model is a well-vetted compromise between sufficient complexity for behavioral analogy to schizophrenia, genetic tractability, and feasibility for high-throughput molecular studies (94,95). Dozens of genetically altered mouse lines model one or more intermediate phenotypes (96,97); here we restrict evidence to the most wellstudied models demonstrating glutamatergic and dopaminergic synergistic molecular and behavioral phenotypes.…”
Section: Preclinical Studies Relating To Schizophrenia Etiologymentioning
confidence: 99%
“…Nevertheless, the mouse model is a well-vetted compromise between sufficient complexity for behavioral analogy to schizophrenia, genetic tractability, and feasibility for high-throughput molecular studies (94,95). Dozens of genetically altered mouse lines model one or more intermediate phenotypes (96,97); here we restrict evidence to the most wellstudied models demonstrating glutamatergic and dopaminergic synergistic molecular and behavioral phenotypes.…”
Section: Preclinical Studies Relating To Schizophrenia Etiologymentioning
confidence: 99%
“…These findings led the field to shift away from a unidimensional conceptualization, in favor of a 2-dimensional conceptualization of negative symptoms. 19 EFA studies supporting the 2 factors have been influential, informing how researchers search for pathophysiological mechanisms of negative symptoms [20][21][22][23][24] and how pharmaceutical companies approach targeted treatment development. 25 However, conclusions about the latent structure of negative symptoms based on EFAs alone are insufficient.…”
mentioning
confidence: 99%
“…Motivation is often defined as an organism's willingness to expend effort for a particular reinforcer, often a reward. This conceptualization is based on effort‐based decision making where reward valuation and an effort calculation are integrated to produce a cost–benefit construct (Barnes et al, 2017; Chong et al, 2016; Der‐Avakian et al, 2016; Epstein & Silbersweig, 2015; Hamill et al, 1999; Randall et al, 2012; Randall, Lee, Nunes, et al, 2014; Randall, Lee, Podurgiel, et al, 2014; Rotolo et al, 2019, 2020, 2021; Stewart et al, 1974; Yohn et al, 2018). Willingness to overcome physical effort (i.e.…”
Section: Discussionmentioning
confidence: 99%
“…Willingness to overcome physical effort (i.e. pressing a lever) that is required to receive a particular reinforcer provides a quantifiable approach for studying motivation in preclinical models (Barnes et al, 2017; Chong et al, 2016; Hamill et al, 1999; Mingote et al, 2005; Salamone & Correa, 2002). Motivation and reward‐value are often quantified by the number of reinforcers an animal earns, also known as break‐point, and the highest ratio completed in a progressive ratio task (Chong et al, 2016; Pipkin & Vollmer, 2009).…”
Section: Discussionmentioning
confidence: 99%